Room for growth

Originally Posted on The Yale Herald via UWIRE

Bluepoint Wellness is tucked behind Planet Fitness in downtown Branford. At the front door, a secretary’s voice greeted me over the intercom as she buzzed me into a small lobby with hardwood floors that smelled like potpourri. The room’s blue walls, adorned with abstract paintings of still life, struck me as more suited to a beach house than a medical marijuana dispensary. Nick Tamborrino, Bluepoint’s founder and owner, entered the room, wearing a bright purple tie over a striped collared shirt. His dark, salt-and-pepper hair was slicked back. A few pens peeked out from his chest pocket.

He swiped us into a series of rooms: “Past all these locked doors,” he chuckled. We walked by a cluster of consultation rooms, also peppered with paintings of flowers. Tamborrino turns my attention to a glass case displaying a series of vaporizers that Bluepoint is encouraging its patients to use as an alternative to smoking.

“As you can see, there’s no marijuana displayed,” he says. “People aren’t sniffing jars like they are out West—this is a very professional set up.”

While Bluepoint is among six Connecticut dispensaries that opened their doors only a few weeks ago, state residents have been able to legally obtain marijuana for several ailments since October 2012 when Connecticut became the seventeenth state to decriminalize medical marijuana. Prior to the opening of state dispensaries, patients who qualified for medical marijuana had to obtain the drug through other means—a difficult task since only a quarter of the states where medical marijuana has been legalized accept medical marijuana ID cards from other states. The dispensary system offers patients a safer, more consistent avenue of obtaining marijuana and a wider variety of strains and potencies from which to choose.

***

A Bluepoint patient receives more than just a dose of weed upon visiting the dispensary; Tamborrino says that Bluepoint mirrors a medical office setting in which patients receive initial consultations, reviews of patient medical history, follow-up appointments, and even a set of treatment goals. Unlike many other states where medical marijuana has been decriminalized, Connecticut’s laws require a pharmacist at every dispensary.

“People think of marijuana dispensaries as what’s going on in Colorado, where it’s all basically recreational and anyone can apply for a license,” Tamborrino said. “That’s not the case here.”

Medical marijuana isn’t available for just any old patient either. Connecticut law states that for a patient to obtain a medical marijuana card, he or she must have one of 11 different medical conditions—from Glaucoma to Multiple Sclerosis—as confirmed by a doctor with whom they have a relationship. According to Samuel Wilkinson, a psychiatrist at the Yale School of Medicine, marijuana has been shown to be effective at alleviating neuropathic pain, nausea in cancer patients, spasticity in Multiple Sclerosis patients, and anorexia in HIV patients, but there is less evidence supporting the outcomes of marijuana use for the other conditions recognized by Connecticut law.

“It’s indicated for PTSD,” Wilkinson said. “Being a psychiatrist, that seems to me a little bit like the cart going before the horse.”

While the use of medical marijuana has been decriminalized by the state, the Federal Drug Administration hasn’t approved medical marijuana in the same way as other medications. Medical marijuana research has been lacking in the kind of rigorous clinical trials that might be used to certify, say, a new blood pressure medication, particularly given that it is still illegal in many states. According to Wilkinson, the use of medical marijuana has been passed so that some patients can take it without legal consequences, but the process has been inconsistent, based on testimonials and surveys rather than hard scientific evidence.

Tamborrino says that Bluepoint is involved in an international study group seeking to measure outcomes for patients receiving various cannabis strains, though Tamborrino admitted that he wouldn’t classify these studies as “clinical trials” per se. On an opt-in basis, these trials will track new Bluepoint patients throughout their experience as the dispensary continues to build on the momentum from these early weeks of its inception.

***

Bluepoint officially opened for business on Wed., Sept. 22 after an exhaustive application—due in November of last year—that included zoning approval, a description of finances in place, and a business plan. Bluepoint was one of six dispensaries awarded a license out of a pool of 27 total applicants.

“When I found we were awarded the license, I couldn’t believe it,” Tamborrino said. “It was so surreal to me. It’s still surreal. From the minute I started the application, I did everything on my own in terms of business planning and envisioning what the characteristics of Bluepoint would be. I can’t tell you how many hours I spent on the application.”

The road to obtaining a dispensary license was hard and long for other dispensary directors, too. Angela D’Amico, owner of the B&D Compassionate Care Center, a dispensary located in Bethel, sighed as she told me, “If you search my name online, you can read all about the municipalities we fought, the zoning appeals from neighbors—there’s a terrible stigma surrounding marijuana.”

A quick Google search does, in fact, support D’Amico’s battle to secure a location for their dispensary. According to an article in the Connecticut Post, she and her partner Karen Barski were denied zoning in both Stratford and Bridgeport before settling on an approved location in Bethel mere days before the license application was due.

Tamborrino said that the town of Branford was welcoming to Bluepoint, but his first choice for a dispensary site was in Norwalk.

“They weren’t as open to this because it’s still new,” he said. “I think people have to understand that Connecticut’s program is a lot different than any other program in the country.”

Although Bluepoint’s program is prioritizing expanding research on medical marijuana legalization, some believe it’s too early to offer pot as a legal consumer product, even within a pharmaceutical setting. Marijuana is an incredibly complex plant, comprised of a mixture of at least 100 different compounds that are combined in varying proportions depending on the strain. Tamborrino told me that not every strain gives off the psychoactive, “high” effect sought by many recreational marijuana users. Part of Bluepoint’s goal is to help patients isolate a strain that works best for their treatment goals, but medical researchers like Wilkinson are skeptical, saying the plant is still too variable at this point in the investigation to predict the effect the strain will have on the individual.

“I think there’s great therapeutic promise in the compounds that comprise marijuana,” Wilkinson said. “But crude marijuana? I just don’t know. I personally would advocate a ‘wait-until’ approach—conducting more research before deciding what is and isn’t safe.”

It’s also not clear how decriminalization will impact how the general population thinks about marijuana. Some argue that further legalization will make marijuana easier to regulate, though Wilkinson points out that alcohol and tobacco, the substances most difficult to keep out of the hands of adolescents, are legal for individuals of age. He has fears, too, about how the substance will be marketed and commercialized as if there are no risks associated with its use. “There’s a greater chance of experiencing negative effects the earlier marijuana is introduced to an adolescent,” Wilkinson said.

Tamborrino, on the other hand, has hopes that decriminalization will remove the stigma surrounding marijuana and educate the public on its potential as an alternative to opiates and other prescription drugs. As we talk, he often returns to the personal stories of patients that have visited Bluepoint in its first few weeks: brain-cancer patients, patients in wheelchairs, a twenty-five-year-old who was hit by a truck when he was twelve, a terminally-ill patient with a few months left, all just trying to improve their quality of life.

“Give the patient a choice for therapy,” Tamborrino said. “Why should a patient be isolated to opiates when they could have the same relief by using a natural plant?”

Connecticut’s medical marijuana industry still has room for growth. Only one of the four growing facilities in the state is distributing marijuana to dispensaries, causing a surge in prices that Tamborrino expects to fall when competition escalates and supply increases. Currently, Bluepoint is only offering five out of the 40-odd strains it expects to sell once grow facilities are up and running. “The prevailing sense is one of hopefulness that it provides relief to those who need it,” said Laurence Grotheer, director of communications for the New Haven mayor’s office. As I exit, I walk back through the three locked doors separating Tamborrino’s office from the rest of Branford. John Mayer plays softly over a stereo system in the lobby. There may be no jars of weed in sight, but that unmistakable odor lingers faintly in the air, then disappears as I step back out onto the parking lot asphalt.

Read more here: http://yaleherald.com/news-and-features/room-for-growth/
Copyright 2026 The Yale Herald